These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34158265)

  • 41. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.
    Miller KC; Gertz MA; Buadi FK; Hayman SR; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Muchtar E; Hogan WJ; Kumar SK
    Bone Marrow Transplant; 2019 Dec; 54(12):2039-2050. PubMed ID: 31190005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
    Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
    Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Vogl DT; Wang T; Pérez WS; Stadtmauer EA; Heitjan DF; Lazarus HM; Kyle RA; Kamble R; Weisdorf D; Roy V; Gibson J; Ballen K; Holmberg L; Bashey A; McCarthy PL; Freytes C; Maharaj D; Maiolino A; Vesole D; Hari P
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1765-74. PubMed ID: 21624486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
    Noring K; Carlsten M; Sonnevi K; Wahlin BE
    BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
    Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.
    Chan H; Phillips M; Maganti M; Farooki S; Piza Rodriguez G; Masih-Khan E; Chen C; Prica A; Reece D; Tiedemann R; Trudel S; Kukreti V
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):225-234. PubMed ID: 29397346
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
    Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
    Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
    Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
    J Hematol Oncol; 2015 Jul; 8():80. PubMed ID: 26138828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of comorbidity on survival and collected CD34 + cell counts in autologous hematopoietic stem cell transplant patients.
    Sarıcı A; Erkurt MA; Kuku İ; Bahçecioğlu ÖF; Biçim S; Kaya E; Berber İ; Keser MF; Gök S; Özgül M
    Transfus Apher Sci; 2022 Feb; 61(1):103296. PubMed ID: 34696982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
    Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
    J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
    Nishihori T; Alsina M
    Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
    Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
    J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
    Munshi PN; Vesole DH; St Martin A; Davila O; Kumar S; Qazilbash M; Shah N; Hari PN; D'Souza A
    Cancer; 2021 Nov; 127(22):4233-4239. PubMed ID: 34374445
    [TBL] [Abstract][Full Text] [Related]  

  • 58. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
    Badar T; Hari P; Dávila O; Fraser R; Wirk B; Dhakal B; Freytes CO; Rodriguez Valdes C; Lee C; Vesole DH; Malek E; Hildebrandt GC; Landau H; Murthy HS; Lazarus HM; Berdeja JG; Meehan KR; Solh M; Diaz MA; Kharfan-Dabaja MA; Callander NS; Farhadfar N; Bashir Q; Kamble RT; Vij R; Munker R; Kyle RA; Chhabra S; Hashmi S; Ganguly S; Jagannath S; Nishihori T; Nieto Y; Kumar S; Shah N; D'Souza A
    Cancer; 2021 Jan; 127(1):82-92. PubMed ID: 32966625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma.
    Dogu MH; Çagirgan S; Ocakci S; Kaya AH; Ilkkilic K; Sanli NM; Kahraman S; Eren R; Tekgunduz E; Hacioglu S; Kaynar L; Erkurt MA; Altuntas F
    Transfus Apher Sci; 2017 Dec; 56(6):814-818. PubMed ID: 29153347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
    Maloney DG; Molina AJ; Sahebi F; Stockerl-Goldstein KE; Sandmaier BM; Bensinger W; Storer B; Hegenbart U; Somlo G; Chauncey T; Bruno B; Appelbaum FR; Blume KG; Forman SJ; McSweeney P; Storb R
    Blood; 2003 Nov; 102(9):3447-54. PubMed ID: 12855572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.